Panoply™ Human CD79B Knockdown Stable Cell Line

Cuproptosis is a novel form of programmed cell death, different from other types such as pyroptosis, ferroptosis, and autophagy. It is a promising new target for cancer treatment. In addition, immune-related genes play a vital role in cancer progression and patient prognosis. Here, the researchers aimed to establish a survival prediction model for lung adenocarcinoma patients based on cuproptosis and immune-related genes to enhance personalized treatment for patients. The researchers collected RNA sequencing (RNA-seq) data of lung adenocarcinoma (LUAD) patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Gene set variation analysis (GSVA) was used to determine the level of immune cell infiltration in the GSE68465 cohort, and weighted gene co-expression network analysis (WGCNA) was used to identify immune-related genes (IRGs). In addition, cuproptosis-related genes (CRGs) were identified using an unsupervised clustering method. The researchers identified five oncogenic driver genes, CD79B, PEBP1, PTK2B, STXBP1, and ZNF671, and established a proportional hazard regression model. The results showed that the high-risk group had significantly lower survival rates in both the training and validation sets. In addition, the high-risk group had lower levels of immune cell infiltration and immune checkpoint expression compared with the low-risk group.

In A549 and H1299 cell lines, the expression level of CD79B was significantly reduced after knocking down CD79B mRNA (Figure 1A). The activity of pancreatic cancer cells was also significantly reduced in CD79B knockdown A549 and H1299 cell lines (Figure 1B). Subsequently, colony formation analysis showed that the ability of CD79B knockdown A549 and H1299 cell lines to form colonies was significantly increased (Figure 1C). The migration ability of CD79B knockdown A549 and H1299 cell lines in wound healing experiments was significantly increased (Figure 1D). In the Transwell experiment, after knocking down CD79B, the invasion ability of A549 and H1299 cell lines was significantly reduced (Figure 1E).

Figure 1. Validates the role of the key gene CD79B in lung cancer cell lines in vitro. (Zhang W, et al., 2023)